Thaler, S., Roßwag, S., & Sleeman, J. P. (2017). Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. OncoTarget, 8(42), . https://doi.org/10.18632/oncotarget.20261
Chicago Style (17th ed.) CitationThaler, Sonja, Sven Roßwag, and Jonathan P. Sleeman. "Proteasome Inhibitors Prevent Bi-directional HER2/estrogen-receptor Cross-talk Leading to Cell Death in Endocrine and Lapatinib-resistant HER2+/ER+ Breast Cancer Cells." OncoTarget 8, no. 42 (2017). https://doi.org/10.18632/oncotarget.20261.
MLA (9th ed.) CitationThaler, Sonja, et al. "Proteasome Inhibitors Prevent Bi-directional HER2/estrogen-receptor Cross-talk Leading to Cell Death in Endocrine and Lapatinib-resistant HER2+/ER+ Breast Cancer Cells." OncoTarget, vol. 8, no. 42, 2017, https://doi.org/10.18632/oncotarget.20261.